Dr. Sherene Loi discusses the development and importance of immune biomarkers in breast cancer, highlighting the TIL biomarker, the limitations of PD-L1, and the potential of new biomarkers to refine treatment algorithms and clinical trials
00:19 - History of immune biomarkers in breast cancer
01:53 - Newer immune biomarkers
02:22 - Implementation of new biomarkers in clinical trials